Fig. 3: Immunity-related transcriptomes are activated during lenvatinib therapy in the TME. | Communications Medicine

Fig. 3: Immunity-related transcriptomes are activated during lenvatinib therapy in the TME.

From: Lenvatinib activates anti-tumor immunity by suppressing immunoinhibitory infiltrates in the tumor microenvironment of advanced hepatocellular carcinoma

Fig. 3

a Heatmap showing clinical characteristics of 8 cases with baseline and 4-week samples analyzed in pairs. Median age was 70.5 years old (47–84) and median PFS was 251 days (95% CI, 123-NA). b Volcano plots showing results for differential RNA expression as quantified by the nCounter system for eight paired (4 W/pre-treatment) samples. Red, p < 0.05 and over a log2 fold change cut-off value of 0.3 (23% increase) or −0.3 (23% decrease). c Visualization of normalized enrichment score for each signature with the nCounter Tumor Signaling Panel 360 (4W/pre-treatment). Dotted line indicates the threshold for the statistical significance of up- and downregulation in 4W samples (P < 0.05). d Representative enrichment plots. Activation of immune response (interferon response, antigen presentation), inactivation of tumor microenvironment (cell adhesion and motility) and inactivation of tumor signaling (Wnt signaling) in on-treatment samples. e Radar plots showing differences in scores of immune infiltrates (ssGSEA value at 4W minus that at baseline). n = 8 pairs (baseline and 4W), (a–d). PFS progression-free survival, RECIST Response Evaluation Criteria in Solid Tumors, CR complete response, PR partial response, SD stable disease, PD progressive disease, TCGA The Cancer Genome Atlas, TME tumor microenvironment, HBV hepatitis B virus, HCV hepatitis C virus, NBNC non-B, non-C hepatic disorder including nonalcoholic fatty liver disease, mut mutant, GSEA Gene Set Enrichment Analysis.

Back to article page